Keywords: Boehringer Ingelheim, Flibanserin, Female sexual arousel, Research

Boehringer Ingelheim’s “female Viagra” flibanserin fails to meet efficacy endpoints, say US FDA reviewers

Article | 17 June 2010

According to documents released yesterday, ahead of a US Food and Drug Administration advisory review panel meeting on Friday (June 18), agency reviewers said that independent German drug major Boehringer Ingelheim’s flibanserin, a drug directed for low female sex drive, failed to meet one of two co-primary efficacy endpoints.

The FDA reviewers concluded that, “in premenopausal women with HSDD, flibanserin 100mg qhs was associated with significant improvements in the number of SSE, sexual desire (measured by FSFI desire), distress associated with sexual dysfunction (measured by FSDS-R and Item 13) and sexual function (measured by FSFI) but did not significantly improve eDiary desire score, compared with placebo. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in